Flare, Persistently Active Disease, and Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: A 2-Year Follow-Up Study

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Conti, Fabrizio ^a   Ceccarelli, Fulvia ^a   Perricone, Carlo ^a   Miranda, Francesca ^a   Truglia, Simona ^a   Massaro, Laura ^a   Pacucci, Viviana Antonella ^a   Conti, Virginia ^a   Bartosiewicz, Izabella ^a   Spinelli, Francesca Romana ^a   Alessandri, Cristiano ^a   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GENERAL ASPECTS OF DISEASE; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; ITALY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PERSISTENTLY ACTIVE DISEASE; SCORING SYSTEM; SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX;

ADULT; ANTIBODIES, ANTINUCLEAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84866695418     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045934     Document Type: Article

References (18)

1. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, et al. (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69: 1269-74.
2. Griffiths B, Mosca M, Gordon C, (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19: 685-708.
3. Gladman DD, Urowitz MB, Kagal A, Hallett D, (2000) Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 27: 377-9.
4. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353: 2550-8.
5. Nikpour M, Urowitz MB, Ibañez D, Gladman DD, (2009) Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 61: 1152-8.
6. Conti F, Ceccarelli F, Perricone C, Massaro L, Spinelli FR, et al. (2010) Low incidence of flare and persistent active disease in a cohort of Italian patients with systemic lupus erythematosus: comment on the article by Nikpour, et al. Arthritis Care Res (Hoboken) 62: 899-900.
7. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB, (2010) Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 37: 1822-7.
8. Gladman DD, Urowitz MB, Keystone EC, (1979) Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 66: 210-5.
9. Walz LeBlanc BA, Gladman DD, Urowitz MB, (1994) Serologically active clinically quiescent systemic lupus erythematosus - predictors of clinical flares. J Rheumatol 21: 2239-41.
10. Hochberg MC, (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
11. Gladman DD, Ibañez D, Urowitz MB, (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29: 288-91.
12. Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, et al. (2000) The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 9: 445-50.
13. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, et al. (1997) The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 40: 809-13.
14. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y, (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11: 593-5.
15. Sciascia S, Ceberio L, Garcia-Fernandez C, Rocatello D, Karim Y, et al. (2012) Systemic lupus erythematosus and infections: Clinical importance of conventional and upcoming biomarkers. Autoimmune Rev: Apr. 1.
16. Romero-Diaz J, Isenberg D, Ramsey-Goldman R, (2011) Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res 63Suppl 11: S37-46.
17. Luijten KM, Tekstra J, Bijlsma JW, Bijl M, (2012) The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment.Autoimmun Rev. 11: 326-9.
18. Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, et al. (2012) Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One 7: e33824.